Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta, Inc. provides life sciences solutions focused on cold-chain sample management, automated storage, consumables, informatics, repository services and multiomics offerings. Its updates commonly cover the Sample Management Solutions and Multiomics businesses, including genomic services, gene synthesis execution, sample storage, high-throughput processing and branded products such as GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro and Barkey.
Azenta news also includes quarterly operating results, guidance updates, long-range planning, governance and leadership changes, customer and research partnerships, and acquisition activity. The completed acquisition of UK Biocentre expanded the company’s sample management, sample storage and processing capabilities in the United Kingdom and added a European operational hub for its Sample Repository Services business.
Azenta (Nasdaq: AZTA) announced a strategic partnership with Frontier Space to test sample management technologies in space as part of the EGGS-2 mission launched in January 2026.
The collaboration used 42 FluidX 0.26mL tubes in a custom container aboard Frontier's SpaceLab Mk 2 to evaluate thermal management, temperature monitoring, and tube durability under launch and spaceflight conditions.
Azenta (Nasdaq: AZTA) reported Q1 fiscal 2026 continuing operations revenue of $149 million, up 1% year-over-year, adjusted EBITDA of $13 million and non-GAAP diluted EPS of $0.09. Gross margin declined to 42.9%, down 380 basis points, while cash and marketable securities totaled $571 million.
The company entered a definitive agreement to sell B Medical Systems for $63 million and authorized a $250 million share repurchase program through 2028. Fiscal 2026 guidance: organic revenue growth of 3–5% and ~300 bps adjusted EBITDA margin expansion.
Azenta (Nasdaq: AZTA) will announce fiscal first quarter 2026 earnings for the period ended Dec. 31, 2025 on Wednesday, Feb. 4, 2026 before the market opens. The company will host a conference call and live webcast to discuss results on Feb. 4, 2026 at 8:30 a.m. Eastern Time. Analysts, investors and media can access the live webcast at https://investors.azenta.com/events. A replay will be available beginning Feb. 5, 2026 at 8:30 a.m. ET.
Azenta (NASDAQ: AZTA) signed a binding agreement to sell its B Medical Systems business to THELEMA S.À R.L. for a purchase price of US$63 million. The sale is expected to close on or before March 31, 2026. Azenta described the divestiture as a step to simplify its portfolio and prioritize core capabilities, and said proceeds will be deployed to strengthen the company and support long-term value creation for shareholders. William Blair served as exclusive financial advisor and Taylor Wessing served as legal counsel.
Azenta (Nasdaq: AZTA) announced a Board-approved $250 million share repurchase program.
The program began on Dec 9, 2025 and runs through Dec 31, 2028 unless earlier extended or terminated. Repurchases may be executed via open-market purchases, privately negotiated transactions, or other methods compliant with Rules 10b-18 and 10b5-1. The authorization is discretionary and does not obligate Azenta to buy any specific dollar amount or number of shares; repurchases can be commenced, suspended, modified, or discontinued at any time.
Management said the buyback is part of a capital allocation strategy alongside productivity, organic growth, and disciplined M&A to enhance long-term shareholder value.
Azenta (Nasdaq: AZTA) reported Q4 FY2025 revenue of $159M (+6% YoY; organic +4%) and full‑year revenue of $594M (+4% YoY; organic +3%).
Fiscal 2025 Adjusted EBITDA was $66M with an Adjusted EBITDA margin of 11.2% (up 310 bps YoY). GAAP operating loss was $27M; GAAP diluted EPS from continuing operations was $0.52 and total diluted EPS was ($1.30). Cash and equivalents plus marketable securities totaled $546M.
Guidance for FY2026 calls for organic revenue growth 3–5% and ~300 bps of adjusted EBITDA margin expansion.
Azenta (Nasdaq: AZTA) will release fiscal fourth quarter and full year 2025 results for the period ended September 30, 2025 on Friday, November 21, 2025 before the market opens.
The company will host a live conference call and webcast to discuss results on November 21, 2025 at 8:30 a.m. Eastern Time. Analysts, investors and media can access the live webcast at https://investors.azenta.com/events. A replay will be available beginning 8:30 a.m. ET on November 22, 2025.
Azenta (Nasdaq: AZTA) announced a strategic partnership with the PRECEDE Foundation on Nov 4, 2025 to support early detection of pancreatic cancer by providing secure biorepository storage and streamlined logistics for PRECEDE study samples.
PRECEDE unites more than 60 academic medical centers and maintains the world's largest high-risk patient cohort combining longitudinal clinical data with biospecimen tracking. Pancreatic cancer currently has a five-year survival rate of 13%, and PRECEDE's stated goal is to raise that to 50% within the next decade. Azenta frames the agreement as reinforcing its position in sample management for clinical and diagnostic research and will support PRECEDE ahead of its Annual Meeting in November.
Azenta (Nasdaq: AZTA) will host an Investor Day on Wednesday, December 10, 2025 at its biorepository facility in Indianapolis, Indiana. The event runs 8:30 AM–3:30 PM ET and includes an invite-only morning facility tour plus afternoon executive presentations and Q&A led by John Marotta (CEO) and Lawrence Lin (EVP & CFO).
The afternoon presentations will be webcast beginning at 1:00 PM ET, with a replay available the following day on Azenta's Investor Relations website. In-person attendance is by invitation and requires advanced registration.
Azenta (Nasdaq: AZTA) reported Q3 fiscal 2025 financial results with revenue from continuing operations at $144 million, flat year-over-year with a 2% organic decline. The company's performance showed mixed results across segments, with Multiomics revenue up 4% to $66 million, while Sample Management Solutions declined 4% to $78 million.
Notable improvements include Adjusted EBITDA of $18 million with a margin of 12.3%, up 260 basis points year-over-year, and Non-GAAP Diluted EPS of $0.19, up from $0.14 last year. The company maintains a strong financial position with $565 million in cash and equivalents. Azenta reiterated its fiscal 2025 guidance, expecting 3-5% organic revenue growth and approximately 300 basis points of Adjusted EBITDA margin expansion.